Clinical trials: Cardiovascular Disease Acute
Stroke
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
- Trial name
- NCT00073476
- Testing
- traxiprodil (CP-101,606)
- Where
- 29 sites in United States, Estonia and 6 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Aortic Arch Aneurysm, Aortic Arch Dissection
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending…
- Conditions
- Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
- Trial name
- ARTIZEN (NCT07089576)
- Testing
- Arcevo™ LSA Hybrid Stent Graft System
- Where
- 26 sites in United States, Germany and 1 more
- Volunteers
- 132 people
- Sponsor
- Artivion Inc.
Ischemic Stroke
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care.
- Trial name
- SP-8203-2002 (NCT04479449)
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Aortic Aneurysm, Penetrating Ulcer
Zenith® TX2® Low Profile TAA Endovascular Graft
The Zenith TX2 Low Profile TAA Endovascular Graft extended study is to collect confirmatory safety and effectiveness data. The Zenith TX2 Low Profile TAA Endovascular Graft is indicated for the treatment of patients with a…
- Conditions
- Aortic Aneurysm, Penetrating Ulcer, Vascular Disease
- Trial name
- NCT02471781
- Testing
- Zenith TX2 Low Profile TAA Endovascular Graft
- Where
- 15 sites in United States
- Sponsor
- Cook Group Incorporated
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
DLBS1033 for the Treatment of Acute Ischemic Stroke
This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.
- Trial name
- NCT02362984
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 9 people
- Sponsor
- Dexa Medica Group
Coronary Arteriosclerosis, Acute Coronary Syndrome
Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking…
- Trial name
- SWAP (NCT00356135)
- Testing
- prasugrel 10 mg, clopidogrel, prasugrel 60 mg
- Where
- 9 sites in United States
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
Heart Failure, Acute Decompensated Heart Failure
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
This is a prospective, multi-center, single-arm, early feasibility study that aims to evaluate the safety of the Impella BTR™ in adult patients requiring left-ventricular hemodynamic support, and to evaluate the effectiveness of…
- Trial name
- BTR EFS (NCT05291884)
- Testing
- Impella BTR
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Abiomed Inc.
Stroke
Virtual Reality in Occupational Therapy Upper Limb Stroke Rehabilitation
The study aims to assess the feasibility of using Resynk, a virtual reality (VR) software platform for upper limb rehabilitation for stroke survivors, both in acute hospital settings and in the community (home, private nursing…
- Trial name
- NCT07032155
- Testing
- Resynk VR session, Using Resynk VR on stroke survivors
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- eXRt Intelligent Healthcare
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies.
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
- Trial name
- ADAPT-HEM (NCT07523555)
- Testing
- Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Beijing Biotech
Myocardial Infarction
A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting
The primary objective of ASSENT 3 Plus (the same as for ASSENT 3) was to evaluate the safety and efficacy of full dose tenecteplase combined with unfractionated heparin (UFH, group A) and full dose tenecteplase combined with…
- Trial name
- ASSENT 3 Plus (NCT02181998)
- Testing
- Full dose tenecteplase, Unfractioned heparin, Enoxaparin
- Volunteers
- 1,606 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
First-in-man Study of the Cerebrovascular Interventional Procedural Control System
The objective of this study the first human use of a new device in treatment of acute ischemic stroke, which to evaluate the feasibility, safety, and efficacy of the Cerebrovascular Interventional Procedural Control System.
- Trial name
- NCT05972252
- Testing
- Cerebrovascular Interventional Procedural Control System
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Dinova Neuroscience Technology Co., Ltd
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT02675452
- Testing
- AMG 176, Azacitidine, Itraconazole
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Acute Ischemic Stroke
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke
The clinical study with UMC119-06 is designed to investigate the safety in patients with acute ischemic stroke ("AIS"). This will be a dose escalation, open-label, single-center study in adult with acute ischemic stroke.
- Trial name
- NCT04097652
- Testing
- UMC119-06
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Meridigen Biotech Co., Ltd.
Sudden Cardiac Arrest, Acute Myocardial Infarction
Improve SCA Bridge Study
The purpose of the Improve SCA Bridge study is to characterize the care pathway flow of post-acute myocardial infarction (MI) patients as a result of standard assessments of left ventricular ejection fraction (LVEF) in the acute…
- Trial name
- NCT03715790
- Testing
- EP referred group, Non-Referred group
- Where
- 52 sites in Bangladesh, Brunei and 14 more
- Volunteers
- 1,491 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Compartment Syndrome
The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome
This is a prospective observational study to determine the reliability and accuracy of Near Infrared Spectroscopy (NIRS) to detect oxygen flow in the extremities of injured and non-injured soldiers over time.
- Trial name
- NCT01171638
- Testing
- Near infrared spectroscopy (NIRS)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- J&M Shuler
Tachycardia
Acute Defibrillation Performance of a Novel Can-less Shock Pathway
Evaluate the operation of the Implantable Subcutaneous String Defibrillator (ISSD) system in patients who require an Implantable Cardioverter Defibrillator (ICD) using an emulator.
- Trial name
- NPC01PRG (NCT02941250)
- Testing
- ISSD emulator
- Where
- Czechia
- Volunteers
- 22 people
- Sponsor
- NewPace Ltd
Ischemic Stroke
Evaluation of the Safety and Performance of Magneto Microcatheter
A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Microcatheter in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.
- Trial name
- NCT04466033
- Testing
- Magneto Microcatheter
- Where
- 3 sites in Hungary, Israel
- Volunteers
- 4 people
- Sponsor
- Magneto Thrombectomy Solutions
Hypercholesterolemia, Myocardial Infarction
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40…
- Trial name
- NCT00202878
- Testing
- ezetimibe/simvastatin, simvastatin
- Volunteers
- 18,144 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.